Glioblastoma study discovers protective role of metabolic enzyme, revealing a novel therapeutic target miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Key protein helps bacteria that causes Legionnaires disease to set up house in host cells
Scientists at UT Southwestern have discovered a key protein that helps the bacteria that causes Legionnaires disease to set up house in the cells of humans and other hosts. The findings, published in
Science, could offer insights into how other bacteria are able to survive inside cells, knowledge that could lead to new treatments for a wide variety of infections.
Many infectious bacteria, from
chlamydia to
salmonella, use systems that allow them to dwell within their host s cells. Better understanding the tools they use to make this happen is teaching us some interesting biochemistry and could eventually lead to new targets for therapy.
E-Mail
IMAGE: A new study suggests that Legionella (red) oscillates between the endoplasmic reticulum (green), and bubble- or tube-shaped structures (blue) to help create or sustain a structure that houses this bacterium. view more
Credit: UT Southwestern Medical Center
DALLAS - May 10, 2021 - Scientists at UT Southwestern have discovered a key protein that helps the bacteria that causes Legionnaires disease to set up house in the cells of humans and other hosts. The findings, published in
Science, could offer insights into how other bacteria are able to survive inside cells, knowledge that could lead to new treatments for a wide variety of infections.
Rutgers Cancer Institute of New Jersey Leader Elected as a Member to the National Academy of Sciences
Eileen White, PhD
Newswise New Brunswick, N.J., April 27, 2021 – Rutgers Cancer Institute of New Jersey Deputy Director, Chief Scientific Officer, and Associate Director for Basic Research Eileen White, PhD, has been elected to the National Academy of Sciences (NAS). She is among 120 members elected this year in recognition of their distinguished and continuing achievements in original research.
The NAS is a private, non-profit society of distinguished scholars charged with providing independent, objective advice to the nation on matters related to science and technology. Members are elected to the NAS by their peers for their outstanding contributions to science. Election to membership in the NAS is considered one of the highest honors that a scientist can receive.
Share:
U.S. FDA Granted Fast Track Designation in 2018
Trial Expected to Enroll 300-400 Patients at Approximately 165 Sites in the U.S. and Europe in Simplified Adaptive Trial Design
Conference Call and Webcast Today at 8:30 a.m. ET
HOUSTON, April 27, 2021 (GLOBE NEWSWIRE) Aravive Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced the Company has dosed the first patient in its Phase 3 trial of AVB-500 in platinum resistant ovarian cancer (PROC). The trial is evaluating the efficacy of AVB-500 in combination with paclitaxel (chemotherapy) and the primary endpoint is progression free survival.